By Katie Sorensen, NP-C | Weight Loss NP
GLP-1 medications are no longer just being discussed as weight loss medications.
They are becoming part of a much bigger conversation about metabolic health, diabetes, cardiovascular risk, inflammation, blood pressure, cholesterol, and long-term prevention.
On August 28, 2026, Eli Lilly announced that the FDA approved Mounjaro, also known as tirzepatide, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.
That includes cardiovascular death, nonfatal heart attack, and nonfatal stroke.
This is a major milestone for Mounjaro. It also gives patients a chance to better understand what GLP-1 and GIP medications may do beyond the number on the scale.
But it is important to be clear about what this new indication does and does not mean.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide. It is a once-weekly injectable medication that works on two hormone pathways: GIP and GLP-1.
It is FDA approved to improve blood sugar in adults and children age 10 and older with type 2 diabetes, along with diet and exercise. Tirzepatide is also the same active medication used in Zepbound, which is approved for chronic weight management in certain patients.
At Weight Loss NP, many patients know tirzepatide because of its weight loss effects. But the medication was first developed in the diabetes space, and the new cardiovascular indication applies specifically to Mounjaro in adults with type 2 diabetes who are at high cardiovascular risk.
This does not mean every patient taking tirzepatide has the same heart-risk indication. Diagnosis, risk factors, medication brand, insurance coverage, and FDA indication all matter.
Learn more about our GLP-1 weight loss programs.
What did the FDA approve?
The FDA approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.
Major adverse cardiovascular events, often called MACE in research, typically include:
- Cardiovascular death
- Nonfatal heart attack
- Nonfatal stroke
This approval was based on the SURPASS-CVOT trial, which included 13,299 adults with type 2 diabetes and established cardiovascular disease. The trial compared Mounjaro with dulaglutide, also known as Trulicity.
According to Lilly, Mounjaro showed an 8% lower rate of major adverse cardiovascular events compared with dulaglutide. However, superiority over dulaglutide was not established.
That’s a notable distinction.
The result supports cardiovascular benefit and safety in a very high-risk type 2 diabetes population, but it does not mean Mounjaro was proven dramatically superior to other GLP-1 medications for heart protection.
Why this matters for patients with type 2 diabetes
People with type 2 diabetes have a higher risk of cardiovascular disease, including heart attack, stroke, and cardiovascular death.
Many patients think of diabetes only as a blood sugar issue. But diabetes is also a vascular and metabolic disease. Blood sugar matters, but so do blood pressure, cholesterol, kidney function, inflammation, weight, sleep apnea, smoking history, family history, and body composition.
This is why modern diabetes and obesity care is shifting.
The goal is no longer just “get the A1C down” or “lose weight.”
The bigger goal is reducing long-term health risk while helping patients feel better, function better, and maintain results.
Mounjaro vs Zepbound: same medication, different indications
This part can be confusing.
Mounjaro and Zepbound both contain tirzepatide, but they are approved for different uses.
Mounjaro is used for type 2 diabetes and now has an additional cardiovascular risk reduction indication for adults with type 2 diabetes who are at high cardiovascular risk.
Zepbound is used for chronic weight management in qualifying patients with obesity or overweight with weight-related health conditions.
That does not mean Zepbound has this same exact cardiovascular indication. It also does not mean patients should switch brands or assume their insurance will cover one medication because another version has a new indication.
A medical provider can help determine which medication, brand, dose, and coverage pathway fits your diagnosis and goals.
What about patients without diabetes?
This new Mounjaro cardiovascular indication is specifically for adults with type 2 diabetes who are at high cardiovascular risk.
For patients without diabetes who are using GLP-1 or GIP/GLP-1 medications for obesity or weight loss, the takeaway is more general: obesity treatment is increasingly being studied for outcomes beyond weight loss.
That is good news.
But we still need to match the evidence to the patient. A person with obesity and no diabetes is not the same as a person with type 2 diabetes and established cardiovascular disease. Trials study specific populations, and FDA indications are based on those populations.
At Weight Loss NP, we help patients understand the difference between promising research, approved indications, insurance coverage, and what is medically appropriate for their own situation.
What this means for medical weight loss
This is where I get a little opinionated.
I do not love when GLP-1 medications are marketed only as a way to get smaller.
That misses the bigger medical picture.
For many patients, medical weight loss is about:
- Reducing diabetes risk
- Improving blood pressure
- Improving insulin resistance
- Reducing inflammation
- Improving sleep apnea risk
- Protecting joints
- Supporting mobility
- Improving fatty liver risk
- Preserving muscle
- Reducing long-term cardiovascular risk
- Building a maintenance plan that actually works
The Mounjaro cardiovascular indication reinforces that these medications belong in a broader metabolic-health conversation.
A good GLP-1 plan should never be just “Here is the shot, good luck.”
It should include medical history review, appropriate medication selection, side effect management, nutrition, protein goals, strength training, lab review when appropriate, dose planning, and long-term maintenance.
Learn more about our medical weight loss services.
Who should ask about cardiovascular risk while taking a GLP-1?
You may want to discuss cardiovascular risk with a provider if you have:
- Type 2 diabetes
- Prediabetes or insulin resistance
- High blood pressure
- High cholesterol
- History of heart attack or stroke
- Family history of early heart disease
- Sleep apnea
- Fatty liver disease
- Chronic kidney disease
- Obesity or abdominal weight gain
- Low activity tolerance
- Smoking history
- Menopause-related metabolic changes
- Low testosterone symptoms with weight gain or insulin resistance
Not every patient needs the same medication. But every patient deserves a plan that looks beyond the scale.
GLP-1 and tirzepatide care in Denver, Arvada, Colorado, Utah, and Florida
Weight Loss NP provides medically supervised GLP-1 and medical weight loss care for patients in Colorado, Utah, and Florida, with local roots in Denver and Arvada.
We help patients understand options like semaglutide and tirzepatide, including how medical history, insurance coverage, medication tolerance, diabetes risk, cardiovascular risk, and long-term goals affect the best treatment plan.
For some patients, tirzepatide may be a strong option. For others, semaglutide, another medication, hormone-informed care, nutrition support, or a maintenance-focused plan may be a better fit.
The right answer depends on the patient.
The bottom line
Mounjaro’s new cardiovascular risk reduction indication is a major development for adults with type 2 diabetes who are at high cardiovascular risk.
It shows how far GLP-1 and GIP/GLP-1 care has moved beyond the old idea that weight loss is only about appearance or willpower. This is good for medicine and good for people!
At the same time, this indication should not be overgeneralized. It applies to Mounjaro in a specific high-risk type 2 diabetes population. It does not mean every tirzepatide patient has the same indication, the same coverage, or the same risk-benefit profile.
The best plan is still individualized.
At Weight Loss NP, we help patients use these medications thoughtfully, safely, and as part of a full metabolic health strategy. Book a free consultation now!
The FDA approved Mounjaro to reduce the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high cardiovascular risk.
Mounjaro and Zepbound both contain tirzepatide, but they have different FDA-approved uses. Mounjaro is labeled for use in people with type 2 diabetes and now has a cardiovascular risk reduction indication for certain high-risk adults with type 2 diabetes. Zepbound is used for chronic weight management in qualifying patients.
GLP-1 medications act on the GLP-1 receptor. Tirzepatide acts on both GIP and GLP-1 pathways, which is why it is often described as a dual GIP and GLP-1 receptor agonist.
This is a medical decision that depends on your diagnosis, cardiovascular history, weight, medications, and risk factors. The new Mounjaro indication is specific to adults with type 2 diabetes at high cardiovascular risk but your specific care plan can vary in coordination with your provider.
+ show Comments
- Hide Comments
add a comment